Electrocardiographic findings of palonosetron in cancer patients

Gonullu G., Demircan S., Demirağ M. K., Erdem D., Yucel I.

SUPPORTIVE CARE IN CANCER, cilt.20, sa.7, ss.1435-1439, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 7
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1007/s00520-011-1226-5
  • Dergi Adı: SUPPORTIVE CARE IN CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1435-1439
  • Anahtar Kelimeler: Palonosetron, 5-HT3 receptor antagonist, P wave, QT interval, QRS complex, MODERATELY EMETOGENIC CHEMOTHERAPY, INTRAVENOUS DOLASETRON MESYLATE, CHILDREN RECEIVING CHEMOTHERAPY, 5-HT3 RECEPTOR ANTAGONIST, DOUBLE-BLIND, PHASE-III, INDUCED NAUSEA, ANTIEMETIC EFFICACY, ACUTE-LEUKEMIA, QT DISPERSION
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Nausea and vomiting are among the major problems occurring during and after the chemotherapy treatments of cancer patients. The recently developed 5-HT3 antagonists have proved much more effective than former agents. Several studies have shown that these agents cause certain ECG changes. We aimed to evaluate the ECG changes caused by palonosetron, one of the new 5-HT3 antagonists.